Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. Urodilatin is produced in the kidney and excreted into the urine, and thus exists in low levels naturally in the systemic blood circulation. When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation.
Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).
Investigated for use/treatment in congestive heart failure.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.